Replimune Group Inc (REPL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Replimune Group Inc stock (REPL) is currently trading at $6.97. Analyst consensus price target for REPL is $12.86. WallStSmart rates REPL as Sell.
- REPL PE ratio analysis and historical PE chart
- REPL PS ratio (Price-to-Sales) history and trend
- REPL intrinsic value — DCF, Graham Number, EPV models
- REPL stock price prediction 2025 2026 2027 2028 2029 2030
- REPL fair value vs current price
- REPL insider transactions and insider buying
- Is REPL undervalued or overvalued?
- Replimune Group Inc financial analysis — revenue, earnings, cash flow
- REPL Piotroski F-Score and Altman Z-Score
- REPL analyst price target and Smart Rating
Replimune Group Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Replimune Group Inc (REPL) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
Replimune Group Inc (REPL) Key Strengths (1)
97.22% of shares held by major funds and institutions
Supporting Valuation Data
Replimune Group Inc (REPL) Areas to Watch (3)
Company is destroying shareholder value
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Replimune Group Inc (REPL) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Market Cap, Price/Book. Some valuation metrics including Price/Book (2.74) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -90.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -90.90% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
REPL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Replimune Group Inc (REPL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Replimune Group Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -66M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Replimune Group Inc.
Bottom Line
Replimune Group Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(1 last 3 months)
| Insider | Type | Shares |
|---|---|---|
ASTLEY-SPARKE, PHILIP Director | Sell | -25,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:22:22 AM
About Replimune Group Inc(REPL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.